Photorefractive keratectomy (PRK) was the first laser refractive surgery approved by the United States Food and Drug Administration in 1996. The improved PRK procedures, including laser epithelial keratomileusis (LASEK), epipolis-laser in situ keratomileusis (epi-LASIK) and transepithelial PRK (trans-PRK), correct refractive errors by permanently altering the shape of the anterior central cornea, and are currently widely used refractive surgeries. Although the methods of performing epithelial debridement are different among these techniques, the ablation of corneal tissue starts from Bowman's membrane using an excimer laser in all of these procedures; accordingly, they are referred to as corneal surface ablation. LASIK, a procedure that was developed later and is distinct from surface ablation, involves the creation of a permanent flap in the deeper layer of the cornea. The LASIK technique has gradually surpassed corneal surface ablation to become the world's most popular refractive surgery ([@b1-prm-20-195]). Nevertheless, a return toward corneal surface ablation has occurred due to better corneal stability ([@b2-prm-20-195],[@b3-prm-20-195]) and no corneal flap complications when compared with LASIK ([@b4-prm-20-195]--[@b7-prm-20-195]). For patients with epithelial basement membrane diseases; thin, flat or steep corneas; and professional athletes who incur risks for physical contact, corneal surface ablation is preferred for correcting refractive errors ([@b8-prm-20-195]). It has been reported that corneal surface ablation is the most commonly performed refractive surgery among members of the United States Air Force ([@b9-prm-20-195]--[@b11-prm-20-195]).

Pain is one of the most common postoperative complications of refractive surgeries, especially after corneal surface ablation ([@b12-prm-20-195]). Most patients experience various degrees of postoperative pain, which can last up to 24 h. Accompanying symptoms include foreign body sensation, photophobia, tearing, stinging, itching and burning sensations. Currently, clinical pain control measures focus on the wearing of an eye-bandage contact lens and administration of pain medications. Given the potential side effects and risks associated with pain medications ([@b13-prm-20-195]--[@b15-prm-20-195]), we conducted the present study to assess the efficacy and safety of a cold patch for treating postoperative pain after trans-PRK.

METHODS
=======

Patients
--------

The present prospective, randomized controlled study was performed in the Department of Ophthalmology, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, China. From March to April 2012, 40 consecutive patients scheduled to undergo refractive surgery for myopia or myopic astigmatism were recruited.

The 40 patients (80 eyes) were randomly assigned to a cold patch group and a wash group (20 patients, 40 eyes each). Patients in the wash (control) group were administered 15 mL of ice-cold balanced salt solution (BSS) during the surgery, but no cold patch was provided after the surgery. Patients in the cold patch group wore a cold patch after the surgery constructed from polyvinyl chloride and filled with cooled antifreeze ([Figures 1](#f1-prm-20-195){ref-type="fig"} and [2](#f2-prm-20-195){ref-type="fig"}), and were not administered BSS during the surgery.

For inclusion in the study, patients had to be ≥18 years of age; with myopia ≤−6D diopter; with stable refractive myopia or myopic astigmatism for \>2 years; and who had stopped wearing soft contact lenses for ≥2 weeks or hard contact lenses for ≥4 weeks before surgery. Patients were excluded if they had a history of eye surgery; had eye diseases such as active anterior segment disease, suspicious keratoconus detected by corneal topography, keratoconus, keratitis, cataracts, glaucoma or ocular fundus diseases; had a systemic disease that affects corneal wound healing such as lupus or diabetes; and if they were pregnant or breastfeeding.

All patients provided signed informed consent before surgery.

Preoperative examination
------------------------

All patients underwent comprehensive ocular examinations before surgery, including uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), subjective refraction using phoropter, anterior segment evaluation using slit-lamp examination, intraocular pressure measurement, tear film breakup time measurement, corneal thickness measurement using ultrasonography and a dilated fundus examination.

Surgical procedures
-------------------

After topical anesthesia with oxybuprocaine, the operated cornea was flushed with BSS (Alcon, USA) and dried carefully using a triangle sponge until the reflection of the corneal surface was uniform, and there was no tear film or crumbs. The corneal epithelium was then removed using the laser; the cutting was stopped when the fluorescence of the corneal epithelium disappeared. The average cut size was 6.5 mm with a depth of 50 μm to 70 μm.

After cutting, the wound was flushed with 15 mL ice-cold (5°C) BSS in the wash group, and eye-bandage contact lenses (Bausch, USA) were worn on all eyes. Eyes in the cold patch group were also covered with bandage contact lenses. Instead of being flushed with ice-cold BSS, the patients in the cold patch group were required to wear a cold patch (cooled to 5°C to 8°C) for 24 h after the surgery. After wearing the cold patch for 30 min, patients were instructed to place it in a refrigerator to cool it for 30 min, then to take it out and put it on again. This procedure was continued until the patients went to sleep in the first 24 h postoperatively.

Postoperative medications included topical tobramycin dexamethasone, levofloxacin, pranoprofen and recombinant human epidermal growth factor eyedrops. Topical oxybuprocaine eyedrops and oral diclofenac sodium were also applied to relieve pain in some patients if they complained of eye pain 24 h after surgery. Oxybuprocaine eyedrops were given for at least 2 h and diclofenac sodium capsules were given (\<100 mg daily).

Postoperative measurements
--------------------------

The pain scores for each patient were recorded during surgery, and at 8 h, 16 h and 24 h after the surgery. Pain was evaluated using a 11-point visual analogue scale (0 = no pain, 10 = worst possible pain).

Evaluation of postoperative eyelid edema was performed using a four-point score: 0 = no palpebral edema; 1 = mild eyelid edema, palpebral fissure was not reduced significantly; 2 = moderate eyelid edema, palpebral fissure narrowed considerably; 3 = severe eyelid edema, palpebral fissure disappeared.

Following surgery, corneal epithelial healing was observed by slit-lamp every 24 h until the epithelium was completely healed. Postoperative conjunctival hyperemia was assessed and recorded according to the following criteria: 0 = no conjunctival hyperemia; 1 = minor conjunctival hyperemia, only in the nasal or temporal side close to the limbus; 2 = conjunctival hyperemia limited to two quadrants; 3 = conjunctival hyperemia spread to four quadrants; 4 = heavy conjunctival hyperemia involving four quadrants with prolapsed edematous conjunctiva.

UCVA, BCVA, manifest refractive spherical equivalent (MRSE) and haze were also recorded in the first and sixth months after surgery, respectively.

Statistical analysis
--------------------

Data analysis was performed using SPSS version 19.0 (IBM Corporation, USA). An independent-samples *t* test was used to compare differences in eyelid swelling between the two groups; *P*\<0.05 was considered to be statistically significant.

RESULTS
=======

All 40 patients included in the present study completed the tests. There was no statistically significant difference in age or degree of MRSE between the two groups. The mean (± SD) age of the patients was 25.5±5.2 years in the cold patch group and 26.2±3.7 years in the wash group (*P*=0.63). The degree of MRSE was −3.85±1.75 diopter in the cold patch group and −4.19±1.56 diopter in the wash group (P=0.36).

The mean epithelium cutting depth was 57.2±16.6 μm in the cold patch group and 58.4±16.8 μm in the wash group, a difference that was not statistically significant (P=0.75). The mean epithelium healing time was 2.6±0.5 days in the cold patch group and 2.8±0.6 days in the wash group; the difference was not statistically significant (P=0.11).

As shown in [Table 1](#t1-prm-20-195){ref-type="table"}, the pain scores of both groups during the surgery were comparable (P=0.46). It was noteworthy that the pain scores in the cold patch group at 8 h, 16 h and 24 h postoperatively were all significantly lower than those in the wash group. Pain relief was evident in all patients 24 h after surgery.

One day after surgery, mean scores for eyelid edema were 0.63±0.34 in the cold patch group and 1.26±0.41 in the wash group; this difference was statistically significant (P\<0.001). No eyelid frostbite occurred in the cold patch group. In addition, the conjunctival hyperemia level was 0.85±0.37 in the cold patch group and 1.57±0.51 in the wash group (P\<0.001).

Regarding the use of painkillers, oxybuprocaine eyedrops were applied 2.32±0.56 times in the cold patch group and 5.61±1.24 times in the wash group. The cold patch group was administered a mean of 1.22±0.25 oral diclofenac sodium capsules and 2.18±0.47 capsules were given to the wash group (P\<0.001).

As shown in [Table 2](#t2-prm-20-195){ref-type="table"}, the UCVA, BCVA, and refractive error and haze of both groups recorded in the first and sixth months after surgery were also not statistically different. Haze was not detected in any eye six months after surgery.

DISCUSSION
==========

Trans-PRK reduces the risk of corneal ectasia and avoids the corneal flap complications associated with LASIK surgery; however, the postoperative pain associated with trans-PRK cannot be ignored. The present study showed that wearing a cold patch after trans-PRK significantly reduced scores for pain and postoperative complications compared with washing with ice-cold BSS during surgery. Moreover, the patients who wore the cold patch used less pain medication.

Clinically, a variety of eye drops or medications are used to relieve pain including nonsteroidal anti-inflammatory drugs, which reduce prostaglandin release by inhibiting cyclooxygenase; glucocorticoids, which reduce stimulation of multiple receptors by inhibiting prostaglandins and many inflammatory mediators such as leukotrienes and bradykinin, and interleukin synthesis ([@b16-prm-20-195]). Local application of topical anesthesia drugs relieves pain by inhibiting sodium-potassium channels and blocking the transmission of nerve impulses. Although all of the above-mentioned drugs can relieve pain, regardless of local, topical or systemic administration, all have associated side effects and risks. For example, topical anesthesia drug abuse can cause delayed corneal epithelial healing, and nonsteroidal anti-inflammatory drugs have occasionally led to serious corneal toxicity ([@b17-prm-20-195]--[@b19-prm-20-195]). Side effects of oral painkillers include kidney failure, peptic ulcers, constipation, pruritus, dizziness, nausea, vomiting and dry mouth ([@b20-prm-20-195],[@b21-prm-20-195]). Therefore, it is necessary to investigate new methods with fewer and less-severe side effects and risks to relieve the postoperative pain associated with trans-PRK.

Presently, there are few studies that have investigated pain relief using physical therapy after laser surface ablation. The mechanism of local hypothermia for pain control involves reducing the transmission of nerve impulses by lowering the temperature, which is similar to that of topical anesthesia. Currently, local hypothermia for alleviating pain is achieved by washing the corneal wound with ice-cold BSS before and after laser cutting. Animal experiments have shown that washing with ice-cold BSS can significantly decrease the temperature of corneas in a rabbit model ([@b22-prm-20-195]). Many surgeons recommend that patients use eye-drops of cold artificial tears to reduce pain after surgery ([@b23-prm-20-195],[@b24-prm-20-195]); however, another study reached the opposite conclusion. Neuffer et al ([@b25-prm-20-195]) found no significant difference in the application of ice-cold or warm BSS during LASEK in a prospective, randomized single-blinded study.

Cold compress is another physical therapy used to relieve pain. Cold water or ice can cool, effect hemostasis, relieve pain, reduce inflammation and promote wound healing. Fujishima et al ([@b26-prm-20-195]) applied cold compresses using ice packs on the eyes for cataract surgery and concluded that most patients were satisfied with this type of physical therapy to relieve pain. Cold compresses work by quickly reducing the surface temperature of the wound. The low temperature leads to local vasoconstriction, a decrease in metabolism, and a decrease in vascular inflammatory factors and bleeding, which inhibit edema. In addition, cold compresses are inexpensive and easy to apply.

The most commonly used cold compress in current clinical practice is the ice pack. However, keeping the ice pack in place is difficult, and the patient's movement is limited. If the ice pack is improperly used, frostbite is possible. Therefore, in the present study, we used a cold patch made from soft polyvinyl chloride material filled with anti-freeze gel. This antifreeze gel ensures that the cold patch does not freeze, even if the ambient temperature is \<0° ([Figure 1](#f1-prm-20-195){ref-type="fig"}). When patients wear a cold patch, they can be in any position because velcro strips at both ends of the cold patch can be used to fix the patch to the occiput ([Figure 2](#f2-prm-20-195){ref-type="fig"}). Patients can even fall asleep when wearing the cold patch. In our study, no patient experienced eyelid frostbite. We speculate that this is due to the abundant blood flow in the eyelid.

A potential limitation of the present study was that we did not compare the corneal temperatures of the two groups due to the lack of appropriate instruments. Although the influence of this limitation on our conclusions is negligible, we will attempt to perform a comparison of corneal temperatures in future work if the instruments become available.

SUMMARY
=======

Wearing a cold patch, as described in the present article, can increase comfort in the surgically treated eyes and reduce the use of pain medication. The cold patch is an effective, safe physical therapy that alleviates eye pain and inflammation after trans-PRK.

![The outer surface of the cold patch is made from soft polyvinyl chloride material. It is filled with antifreeze gel, which does not freeze, even in environments in which the ambient temperature is \<0°C](prm-20-195-1){#f1-prm-20-195}

![A patient wearing a cold patch while sitting. Velcro at both ends of the cold patch fixes the patch on the occiput, which ensures that patients can be in any position while wearing the cold patch.](prm-20-195-2){#f2-prm-20-195}

###### 

Comparison of pain scores between the two groups at different time points

                   **Cold patch (n=20)**   **BSS wash (n=20)**   **P**
  ---------------- ----------------------- --------------------- -------
  During surgery   2.56±1.29               2.89±1.51             0.46
  Postoperative                                                  
    8 h            2.32±1.31               3.41±1.63             0.025
    16 h           2.16±0.81               3.25±1.03             0.001
    24 h           1.16±0.68               2.02±0.79             0.001

Data presented as mean ± SD unless otherwise indicated. BSS Balanced salt solution

###### 

Comparison of postoperative uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), mean refractive spherical equivalent (MRSE) error and haze between the cold patch (n=40) and wash (n=40) groups one and six months after surgery

  ---------------- --------------- ---------------- ---------------- -------------- ----------- ------
                   **One month**   **Six months**                                               
                                                                                                
  **Cold patch**   **BSS wash**    **P**            **Cold patch**   **BSS wash**   **P**       
                                                                                                
  UCVA             0.91±0.24       0.83±0.23        0.13             1.02±0.21      0.98±0.26   0.45
  BCVA             0.96±0.36       0.89±0.40        0.41             1.16±0.19      1.04±0.17   0.62
  MRSE (D)         0.86±0.24       0.82±0.31        0.52             0.42±0.30      0.50±0.37   0.29
  Haze             0.22±0.14       0.26±0.17        0.25             None           None        --
  ---------------- --------------- ---------------- ---------------- -------------- ----------- ------

Data presented as mean ± SD unless otherwise indicated. BSS Balanced salt solution; D Diopter
